– Bloomberg
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment At Stanford Medicine; FemBloc Is Being Developed As A First- Of-Its-Kind, Non-Surgical Permanent Birth Control With A Clearly Defined U.S. Regulatory Pathway
- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second academic center to participate in the FemBloc pivotal trial since enrollment began last
